(b)(4).During processing of this complaint, attempts were made to obtain complete event, patient and device information.Concomitant medical products: 3.0x23mm and 4.0x18mm xience pro stents; 6f guide catheter.The device was not returned for analysis.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.Additionally, a review of the complaint history identified no other incidents from this lot.It should be noted that the reported patient effect of stenosis is listed in the xience pro a everolimus eluting coronary stent systems instructions for use as a known patient effect of coronary stenting procedures.The investigation was unable to determine a conclusive cause for the reported difficulty to deploy.There is no indication of a product quality issue with respect to manufacture, design or labeling.The additional two xience proa devices referenced are being filed under separate medwatch reports.
|
It was reported that on (b)(6) 2019, a 2.5x23mm, 3.0x23mm, and 4.0x18mm xience pro stents were implanted in the right coronary artery lesion.Stent under-expansion was noted for all three stents, requiring additional post-dilatation with a balloon catheter.Post-procedure, there was 0% diameter stenosis.On (b)(6) 2019, in-stent restenosis was observed in the 2.5x23mm xience pro stent.Another stent was implanted as treatment.The event resolved without sequela.No additional information was provided regarding this issue.
|